nach oben

Erschienen in:

12.10.2022 | Stammzell-Transplantation | Schwerpunkt

Schwerpunkt "AML - Teil 2: alloSCT und Rezidivtherapie"

Stellenwert der allogenen Stammzelltransplantation bei AML

verfasst von: Dr. med. Evgeny Klyuchnikov

Erschienen in: InFo Hämatologie + Onkologie | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Auszug

Trotz Verbesserung der Ergebnisse nach alloSCT über die letzten Jahre bleibt die Toxizität der Fremdspendertransplantation höher als die nach Chemotherapie bzw. autologer SCT. Der Graft-versus-Leukämie-Effekt führt allerdings auch zu einer deutlich geringeren Rezidivrate, insbesondere bei Hochrisiko-Patient*innen. Verbessert durch eine molekulare Therapiesteuerung stellt die alloSCT eine kurative Behandlungsoption für Hochrisikoerkrankte dar, die durch Einsatz von neuen Medikamenten weiter verfeinert werden kann. …

Thomas ED et al. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med. 1957;257(11):491-6

Appelbaum FR. Hematopoietic-Cell Transplantation at 50. N Engl J Med. 2007;357(15):1472-5

Cornelissen JJ et al. Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. J Clin Oncol. 2012;30(17):2140-6

Ustun C et al. Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia. 2019;33(11):2599-609

Bacigalupo A et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12): 1628-33

Horowitz MM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75(3):555-62

Cornelissen J et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012;9(10):579-90

Wheatley K et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol. 1999;107(1):69-79

Grimwade D et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-65

10.

Döhner H et al. Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. Blood. 2022; https://doi.org/jc2z

11.

Loke J et al. Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How? Front Immunol. 2021;12:659595

12.

Walter RB et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol. 2011;29(9):1190-7

13.

Hourigan CS et al. Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. J Clin Oncol. 2020;38(12):1273-83

14.

Tauro S et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol. 2005;23(36):9387-93

15.

Weisdorf DJ et al. Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission. Cancer. 2017;123(11):2025-34

16.

Gilleece MH et al. Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT. Leukemia. 2019;34(1):87-99

17.

Craddock C et al. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia. 2011;25(5):808-13

18.

Schmid C et al. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood. 2012;119(6):1599-606

19.

Christopeit M et al. Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. J Clin Oncol. 2013;31(26):3259-71

20.

Koreth J et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301(22):2349-61

21.

Bornhaeuser M et al. Allogeneic Hematopoietic Cell Transplantation in Patients ≤ 60 Years with Intermediate-Risk Acute Myeloid Leukemia in First Remission - Results of the Randomized Etal-1 Trial-. Blood. 2021;138(Suppl_1):173

22.

Herold T et al. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 2020;34(12):3161-72

23.

Fenwarth L et al. A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia. Blood. 2021.28;137(4):524-32

24.

Venditti A et al. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Blood. 2019;134(12):935-45

25.

Jourdan E et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood. 2013;121(12):2213-23

26.

Ivey A et al. Assessment of Minimal Residual Disease in Standard-Risk AML. N Engl J Med. 2016;374(5):422-33

27.

Craddock C et al. Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia. J Clin Oncol. 2021;39(7):768-78

28.

Loke J et al. The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience. Br J Haematol. 2020.188(1):129-46

29.

Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood. 2016;127(1): 62-70

30.

Brunet S et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol. 2012;30(7):735-41

31.

Sorror ML et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-9

32.

Sorror ML et al. Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation. J Clin Oncol. 2014;32(29):3249-56

33.

Schiffer C et al. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood. 1989;73(1):263-70

34.

Muffly L et al. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017;130(9):1156-64

35.

Lancet JE et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018;36(26):2684-92

36.

Stone RM et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017; 377(5): 454-64

37.

Abdul Wahid SF et el. Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis. Stem Cells Dev. 2014;23(21):2535-52

38.

Scott BL et al. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol. 2017;35(11):1154-61

39.

Bornhäuser M et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol. 2012;13(10):1035-44

40.

Fasslrinner F et al. Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. Lancet Haematol. 2018;5(4):e161-e9

41.

Dillon R et al. Molecular MRD status and outcome after transplantation in NPM1-mutated AML. Blood. 2020;135(9):680-8

42.

Schmid C et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol. 2007;25(31):4938-45

43.

Hofmann S et al. Donor Lymphocyte Infusion Induces Polyspecific CD8+ T-Cell Responses With Concurrent Molecular Remission in Acute Myeloid Leukemia With NPM1 Mutation. J Clin Oncol. 2013;31(3):e44-7

44.

Wermke M et al. Successful treatment of molecular relapse in NPM1-positive AML using 5- azacytidine. Leukemia. 2010;24(1):236-7

45.

Craddock C et al. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica. 2016;101(7):879-83

46.

Alizadeh M et al. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood. 2002;99(12):4618-25

47.

McSweeney PA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graftversus-tumor effects. Blood. 2001;97(11):3390-400

48.

Klyuchnikov E et al. Post-Transplantation Day +100 Minimal Residual Disease Detection Rather Than Mixed Chimerism Predicts Relapses after Allogeneic Stem Cell Transplantation for Intermediate-Risk Acute Myelogenous Leukemia Patients Undergoing Transplantation in Complete Remission. Transplant Cell Ther. 2022;28(7):374.e1-374.e9

49.

Quek L et al. Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia. Blood Adv. 2016;1(3):193-204

50.

Jan M et al. Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. Blood Adv. 2019;3(14):2199-204

51.

Goodyear O et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood. 2012;119(14):3361-9

52.

Craddock C et al. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica. 2016;101(7):879-83

53.

Platzbecker U et al. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol. 2018;19(12):1668-79

54.

Oran B et al. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv. 2020;4(21):5580-8

55.

Schmid C et al. Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT. Br J Haematol. 2019;184(5):782-7

56.

IMPACT Partnership. PRO-DLI: A Phase II Prospective Trial of Prophylactic Donor Lymphocyte Infusions for the Prevention of Relapse post HSCT in patients with High Risk Myeloid Malignancy. www.impactpartnership.org.uk/the-trials/pro-dli abgerufen am 20. September 2022

57.

Greiner J et al. Immunological and Clinical Impact of Manipulated and Unmanipulated DLI after Allogeneic Stem Cell Transplantation of AML Patients. J Clin Med. 2019;9(1):39

58.

Burchert A et al. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). J Clin Oncol. 2020;38(26):2993-3002

59.

Schlenk RF et al. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood. 2019;133(8):840-51

60.

ClinicalTrials.gov. National Library of Medicine (U.S.). A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML). Identifier NCT02997202. https://clinicaltrials.gov/ct2/show/ NCT02997202 abgerufen am 20. September 2022

61.

Kayser S, Levis MJ. Advances in targeted therapy for acute myeloid leukaemia. Br J Haematol. 2018;180(4):484-500

62.

ClinicalTrials.gov. National Library of Medicine (U.S.). Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the PostTransplant Setting. Identifier NCT04128501. https:// clinicaltrials.gov/ct2/show/NCT04128501 abgerufen am 20. September 2022

63.

ClinicalTrials.gov. National Library of Medicine (U.S.). (2000, February 29 -). A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) (VIALE-T). Identifier NCT04161885. https://clinicaltrials.gov/ct2/show/NCT04161885 abgerufen am 20. September 2022

64.

Kent A et al. Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse. Blood Adv. 2020;4(13):3102-8

65.

Roboz GJ et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood.2020;135(7):463-71

66.

DiNardo CD et al. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med. 2018; 378(25):2386-98

67.

Stein EM et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722-31

68.

ClinicalTrials.gov. Enasidenib as Maintenance Therapy in Treating Patients With Acute Myeloid Leukemia With IDH2 Mutation After Donor Stem Cell Transplant. Identifier NCT03728335. https://clinicaltrials.gov/ct2/show/ NCT03728335 abgerufen am 20. September 2022

69.

ClinicalTrials.gov. IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation. Identifier NCT03564821. https://clinicaltrials.gov/ct2/show/NCT03564821 abgerufen am 20. September 2022

Titel: Schwerpunkt "AML - Teil 2: alloSCT und Rezidivtherapie"
Stellenwert der allogenen Stammzelltransplantation bei AML
verfasst von: Dr. med. Evgeny Klyuchnikov
Publikationsdatum: 12.10.2022
Verlag: Springer Medizin
Schlagwörter: Stammzell-Transplantation
Akute myeloische Leukämie
Stammzell-Transplantation
Stammzell-Transplantation
Erschienen in: InFo Hämatologie + Onkologie / Ausgabe 10/2022
Print ISSN: 2662-1754
Elektronische ISSN: 2662-1762
DOI: https://doi.org/10.1007/s15004-022-9715-x

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Stellenwert der allogenen Stammzelltransplantation bei AML

Auszug

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2022

Kardiotoxizität: QT-Formel relevant?

Zulassungserweiterung für BTK-Inhibitor

Melanom: Neues in der Adjuvanz

Schwangerschaft nach Brustkrebserkrankung

Operationsberichte: Wie detailliert müssen sie sein?

Messung der ctDNA hilft bei Entscheidung für oder gegen adjuvante Chemotherapie

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie